A point prevalence surveillance study from pediatric and neonatal specialty hospitals in India

Journal of Pediatric Infectious Diseases

Volumn 9, Issue 3, 2014, Pages 151-155

  Singh, Sanjeev ^a   Jose, Tency ^a   Versporten, Ann ^b   Sengupta, Sharmila ^c   Fini, P ^a   Sharland, Mike ^d   Kumar, R Krishna ^a   Goossens, Herman ^b  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c BL Kapoor Hospital   (India)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antimicrobial resistance; Point prevalence surveys; Prophylaxis

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; FLUCONAZOLE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED INFECTION; EVIDENCE BASED PRACTICE; FEMALE; GASTROINTESTINAL INFECTION; HEALTH SURVEY; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HUMAN; INDIA; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NEWBORN; NEWBORN INTENSIVE CARE; PEDIATRIC HOSPITAL; POINT PREVALENCE SURVEY; PRESCRIPTION; RESPIRATORY TRACT INFECTION; REVIEW; SURGICAL PATIENT; URINARY TRACT INFECTION; WARD;

EID: 84911114577     PISSN: 13057707     EISSN: 13057693     Source Type: Journal    
DOI: 10.3233/JPI-140429     Document Type: Review

References (11)

1. World Health Organisation. Report on the Burden of Endemic Healthcare Associated Infections worldwide. Geneva: WHO; 2011.
2. European Center for Disease Prevention and Control. Anti-microbial resistance surveillance in Europe 2010. Annual report of the European Antimicrobial Resistance Surveillance Network. Stockholm: ECDC 2011.
3. Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, Lundborg CS, Söderström A, Torell E, Cars O. Sustained reduction of antibiotic use and low bacterial re-sistance: 10-year follow-up of the Swedish Strama pro-gramme. Lancet Infect Dis 2008;8(2):125-32.
4. French GL, Cheng AF, Wong SL, Donnan S. Repeated prevalence surveys for monitoring effectiveness of hospital infection control. Lancet 1989;2(8670):1021-3.
5. Health Protection Scotland. Scottish National Prevalence Survey of Healthcare Associated Infection and Antimicrobial Prescribing Data Collection Protocol v1. Glasgow: Health Protection Scotland; 2011.
6. Information Service Division Scotland [homepage on the In-ternet] . Name of the city: Hospital Classification. Information Services Division 2011 [cited 2012 Mar 22] ; Available from: http://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=Costs-Hospital-ttp://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=Costs-Hospital-Class.xls&pContentDispositionType=inline
7. VersportenA, Sharland M, Bielicki J, Drapier N, Vankerckhoven V, Goossens H; ARPEC Project Group Members. The antibiotic resistance and prescribing in Euro-pean Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis J 2013;32(6):e242-53.
8. Ghafur A, Mathai D, Muruganathan A, Jayalal JA, Kant R, Chaudhary D et al. The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial resistance. Indian J Cancer 2013;50(1):71-3.
9. Reilly JS, Price L, Godwin J, cairns S, Hopkins S, Cookson B et al. Pilot validation study of the ECDC point prevalence survey of healthcare associated infections and antmicrobial use in European acute care hospitals, Glasgow: Glasgow Caledonian University; 2012.
10. Malcolm W, Cromwell T. Scottish Antimicrobial Prescribing Group European Surveillance of Antimicrobial Consumption Point Prevalance Survey 2009 Scottish Hospitals Report. Scotland: Health Protection Scotland;Information Services Division; 2012.
11. Public Health update of Carbapenum-Resistant Enterobacte-riaceae (CRE) producing metallo-beta-lactamases in the US reported to CDC. Center for Disease Control and Prevention 2011 (cited 2012 Mar 27).